Expertise in
2
conditions

Dr. Lora J. Mcgill

Neurology
Office
6401 Poplar Ave Ste 420, 
Memphis, TN 
Expertise in
2
conditions
Office
6401 Poplar Ave Ste 420, 
Memphis, TN 

Overview

Lora Mcgill is a Neurologist practicing medicine in Memphis, Tennessee.

Dr. Mcgill is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Migraine with Brainstem Aura, Familial Hemiplegic Migraine, Migraine, and Alzheimer's Disease.

She is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 11 clinical trials.

Specialties

Neurology

Licenses

Psychiatry & Neurology in TN

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

Office
6401 Poplar Ave Ste 420, Memphis, TN 38119

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
LY2951742 Biomarker Study in Patients With Migraine
LY2951742 Biomarker Study in Patients With Migraine
Enrollment Status: Completed
Publish Date: April 09, 2019
Intervention Type: Drug
Study Phase: Early Phase 1
View 9 Less Clinical Trials

2 Total Publications

Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials.
Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials.
Journal: Headache
Published: October 18, 2021
Similar Doctors
Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Veracity Neuroscience LLC

5050 Poplar Avenue, Suite 511, 
Memphis, TN 
 (3.6 miles away)
901-443-9170
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Ledoux is a Neurologist practicing medicine in Memphis, Tennessee. Dr. Ledoux is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Focal Dystonia, Drug Induced Dyskinesia, Benign Essential Blepharospasm, and Movement Disorders. Dr. Ledoux is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Semmes-Murphey Clinic

6325 Humphreys Blvd, 
Memphis, TN 
 (3.2 miles away)
901-522-7700
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nitin Goyal is a Neurologist practicing medicine in Memphis, Tennessee. Dr. Goyal is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Stroke, Scaphoid Non-Union, Cerebral Arteriovenous Malformation, Thrombectomy, and Stent Placement. Dr. Goyal is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Le Bonheur Children's Hospital

848 Adams Ave, 
Memphis, TN 
 (11.3 miles away)
901-287-5437
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lucas Elijovich is a Neurologist practicing medicine in Memphis, Tennessee. Dr. Elijovich is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Stroke, Subarachnoid Hemorrhage, Brain Aneurysm, Thrombectomy, and Stent Placement. Dr. Elijovich is currently accepting new patients.

Frequently Asked Questions about Dr. Lora J. Mcgill

How do I make an appointment with Dr. Lora J. Mcgill?

You can book an appointment with Dr. Lora J. Mcgill by calling their office at 901-843-1045. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lora J. Mcgill a top-rated expert for Migraine with Brainstem Aura?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lora J. Mcgill is classified as an Advanced expert for Migraine with Brainstem Aura, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lora J. Mcgill specialize in?

While Dr. Lora J. Mcgill is a Neurology, they have specific expertise in Migraine with Brainstem Aura, Familial Hemiplegic Migraine, and Migraine. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Lora J. Mcgill participate in research or clinical trials?

Yes. Dr. Lora J. Mcgill has published 2 articles and abstracts on conditions like Migraine with Brainstem Aura. You can view a list of Dr. Lora J. Mcgill's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lora J. Mcgill accept my insurance?

Dr. Lora J. Mcgill accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 901-843-1045 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcgill's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile